Regeneron Pharmaceuticals: Melanoma trials

The registry lists 12 Melanoma studies with Regeneron Pharmaceuticals as lead sponsor. 3 are open to participants now and 2 have results posted.

Phase 1 4Phase 2 5Phase 3 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma TreatmentEnrolling by invitationNCT06848088Phase 2
• A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their BodyRecruitingNCT06413680Phase 1/2
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)RecruitingNCT06246916Phase 3
• CMP-001 in Combination With Nivolumab in Subjects With Advanced MelanomaTerminatedNCT04698187Phase 2Results posted
• CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced MelanomaTerminatedNCT04695977Phase 2/3Results posted
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaActive, not recruitingNCT06190951Phase 2
• Compassionate Use of VidutolimodNo longer availableNCT06063746
• A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryActive, not recruitingNCT05608291Phase 3
• Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic MelanomaActive, not recruitingNCT05352672Phase 3
• Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced MelanomaCompletedNCT03084640Phase 1
• An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)CompletedNCT03002376Phase 1
• Clinical Study of CMP-001 in Combination With Pembrolizumab or as a MonotherapyCompletedNCT02680184Phase 1